Navigation Links
Lorus Therapeutics Announces Scientific Presentations for Lead,Antisense and siRNA Drug Candidates at International Cancer,Conference

98th Annual Meeting of the American Association for Cancer Research (AACR)

TORONTO, April 17, 2007 /PRNewswire-FirstCall/ - Lorus Therapeutics Inc. ("Lorus") today announced presentation of research on their lead antisense and siRNA compounds at the 98th Annual Meeting of the AACR in Los Angeles, CA, April 14-18, 2007.

The first presentation titled, "Determination of optimized administration schedule of GTI-2040 and docetaxel combination treatment for NSCLC cells in vitro and in vivo," was presented on April 15, 2007.

This research determined a new optimal dosing schedule of GTI-2040 and docetaxel, which resulted in greatly enhanced synergy when docetaxel was given 48 hours after GTI-2040 compared to concomitant administration. This strong synergy was seen in vivo even after a single dose of GTI-2040. The discovery that administration of GTI-2040 prior to docetaxel is associated with this synergy, possibly through a 'stressor' effect due to decreased levels of R2 target expression, may potentially apply to other GTI-2040 combinations as well. This new sequential dose strategy will be an important consideration to maximize efficacy in the GTI-2040 clinical program.

The second presentation titled, "siRNAs targeting the R2 subunit of human ribonucleotide reductase exhibit in vitro and in vivo antitumor activity," will be presented on April 17, 2007.

In this research, Lorus screened a series of siRNAs to select a lead drug candidate, siRNA-1284. siRNA-1284 demonstrated potent antiproliferative and antitumor activity both in vitro and in vivo, coinciding with specific target silencing. These data warrant further development of siRNA-1284 as an anticancer agent. Lorus is also pursuing other cancer targets with its siRNA platform technology to screen and evaluate novel siRNA drug candidates.

"The research announced today provides important supporting data for Lorus' drug development
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
4. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
5. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
6. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
7. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
8. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
9. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
10. Trophos Publishes ALS Article in Journal of Pharmacology and Experimental Therapeutics
11. Novelos Therapeutics Announces Encouraging Results in Ongoing Phase 2 Ovarian Cancer Trial at Dana-Farber/Partners Cancer Care
Post Your Comments:
(Date:9/18/2014)... Mich. , Sept. 18, 2014  A $3 ... will allow the University of Michigan to establish a ... The Glenn Center for Aging Research at U-M ... that drugs can slow the effects of aging and ... mechanisms of aging that can help develop medications that ...
(Date:9/18/2014)... --  3D Systems   (NYSE: DDD ) announced ... a new robotic surgery skills and procedural training simulator, which ... exhibition in Amsterdam, The Netherlands from ... invasive surgery represents a growing portion of overall surgical volume, ... robotic surgery has increased, and it is expected that this ...
(Date:9/18/2014)... , Sept. 18, 2014  Halozyme Therapeutics, Inc. ... the U.S. Food and Drug Administration (FDA) has ... dosing of PEGPH20 in SWOG,s ongoing Phase 1b/2 ... evaluate Halozyme,s investigational drug PEGPH20 (PEGylated Recombinant Human ... in patients with metastatic pancreatic adenocarcinoma.  The study ...
Breaking Medicine Technology:$3 M grant funds Paul F. Glenn Center for Aging Research at the University of Michigan 2$3 M grant funds Paul F. Glenn Center for Aging Research at the University of Michigan 33D Systems Introduces New Simbionix Robotics Training Platform 23D Systems Introduces New Simbionix Robotics Training Platform 3SWOG To Resume Clinical Trial Of Halozyme's PEGPH20 In Combination With Modified FOLFIRINOX For Advanced Pancreatic Cancer 2SWOG To Resume Clinical Trial Of Halozyme's PEGPH20 In Combination With Modified FOLFIRINOX For Advanced Pancreatic Cancer 3SWOG To Resume Clinical Trial Of Halozyme's PEGPH20 In Combination With Modified FOLFIRINOX For Advanced Pancreatic Cancer 4
... Surgical, recently named one of Philadelphia,s 100 Fastest ... the healthcare marketplace with the acquisition of the ... surgical facilities to Millennium Surgical,s resources.  Its acquisition ... company has been undertaking for several years.  Millennium ...
... March 23, 2011 Polar ( ... assessment technology, today announced a partnership with celebrity fitness trainer ... president and CEO of NGR™ / No Gym Required™ ... a new show on the CW network, as a spokesperson ...
Cached Medicine Technology:Millennium Surgical adds "SurgicalInstruments.com" Name 2Polar Partners with 'Shedding for the Wedding' Trainer and NGR™ President and CEO Jennifer Cohen 2Polar Partners with 'Shedding for the Wedding' Trainer and NGR™ President and CEO Jennifer Cohen 3
(Date:9/18/2014)... NJ (PRWEB) September 18, 2014 ... firm, announced today that President and co-founder John ... Journal’s Innovation Award Winners for 2014, recognizing the ... him as an emerging executive of the year. ... care and life sciences that continue to shape ...
(Date:9/18/2014)... Qualis Health, one of the nation’s leading ... paper, “Advancing Primary Care through the Patient-Centered Medical Home ... Authors Jeff Hummel, MD, MPH and Peggy C. Evans, ... in the work of becoming a Patient-Centered Medical Home ... objectives, such as generating and providing useful data that ...
(Date:9/18/2014)... Baltimore, MD (PRWEB) September 18, 2014 ... Award-winning celebrity and wellness advocate, and Frank Davis, ... Activz Whole-food Nutrition, are pleased to announce ... 150+ ways to make delicious, nutrition-packed meals using ... book is the next step in the ...
(Date:9/18/2014)... of international scientists have developed a new method to ... . , The Wildlife Conservation Society (WCS)-led research, published ... , describes the use of fecal samples from wild ... exposed to the virus. This represents a new tool ... change the way Ebola virus is studied and improve ...
(Date:9/18/2014)... expect to pay higher employee contributions for their health ... officers about the impact of the Patient Protection and ... conducted by the Darla Moore School of Business at ... Patrick Wright, a professor in strategic human resource management, ... Officers. The survey is distributed to more than 560 ...
Breaking Medicine News(10 mins):Health News:TayganPoint Executive Receives Prestigious Award from Philadelphia Business Journal 2Health News:Advancing Primary Care Through PCMH and HIT: New White Paper Connects the Dots 2Health News:Montel Williams and Frank Davis Announce New Whole-Food Nutrition Recipe Book, The Simple Scoop, at Natural Products Expo East In Baltimore 2Health News:Montel Williams and Frank Davis Announce New Whole-Food Nutrition Recipe Book, The Simple Scoop, at Natural Products Expo East In Baltimore 3Health News:Research yields a game changer for improving understanding of Ebola and great apes 2Health News:Research yields a game changer for improving understanding of Ebola and great apes 3Health News:Survey: Fortune 500 employees can expect to pay more for health insurance 2Health News:Survey: Fortune 500 employees can expect to pay more for health insurance 3
... regional networks , , FRIDAY, April 24 (HealthDay News) ... laboratory personnel has led to steady improvements in the ... a severe heart attack, new research shows. , The ... ST elevation myocardial infarction (STEMI), the deadliest type of ...
... Though soldiers tend to be healthier, trauma erases the advantage, ... Those serving in the armed forces tend to be in ... experienced combat duty, that initial health advantage is erased. , ... life than do non-combat veterans, according to a study that ...
... N.C. (April 23, 2009) Talecris Biotherapeutics, Inc. ... of life results from the largest clinical trial ... polyneuropathy (CIDP) in the April 14, 2009 issue ... that long-term treatment with Gamunex (Immune Globulin Intravenous ...
... ANGELES , April 24 MMR Information ... its wholly-owned operating subsidiary, MyMedicalRecords, Inc. (collectively, "MMR") ... www.mymedicalrecords.com ) and electronic safe deposit box ... a Webinar on the company,s products for healthcare ...
... ABC,s hit television show Grey,s Anatomy has selected the ... its favorite charities and has listed the AAN Foundation on the Grey,s ... and Dr. Derek "McDreamy" Shepherd. Fans and the public are encouraged ... lieu of gifts. The public can buy a virtual brain for ...
... "Pregnant women need our assistance now so that abortion ... April 24 Cardinal Rigali, chair of the Committee ... Bishops (USCCB), wrote to all U.S. Representatives urging them ... 2035) re-introduced in the House by Rep. Lincoln Davis ...
Cached Medicine News:Health News:Coordination Has Led to Quicker Heart Treatment 2Health News:Combat Duty Harms Long-Term Health of Vets 2Health News:Combat Duty Harms Long-Term Health of Vets 3Health News:Landmark study demonstrates Gamunex improves health-related quality of life in patients with CIDP 2Health News:Landmark study demonstrates Gamunex improves health-related quality of life in patients with CIDP 3Health News:MMR Announces Webinar to Demonstrate MyMedicalRecords PHR Product Line 2Health News:MMR Announces Webinar to Demonstrate MyMedicalRecords PHR Product Line 3Health News:AAN Foundation Benefits from Grey's Anatomy 'Wedding Registry' 2Health News:Cardinal Rigali Praises House Re-Introduction of 'Pregnant Women Support Act,' Urges Co-Sponsorship 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: